ライフサイエンスコーパス: beta-blocker

1 he world and Cmpd-15 is the first allosteric beta-blocker.

2 ypoglycemia observed in infants treated with beta blockers.

3 set were several surfactants and a series of beta-blockers.

4 y stage of PHT may influence the response to beta-blockers.

5 angiotensin-converting enzyme inhibitors or beta-blockers.

6 nce, older age, male sex, and treatment with beta-blockers.

7 ty-five percent were previously treated with beta-blockers.

8 dies have compared the efficacy of different beta-blockers.

9 creased survival of patients on nonselective beta-blockers.

10 ved regardless of heart rhythm or receipt of beta-blockers.

11 nditionally recommend the use of in-hospital beta-blockers.

12 Use of systemic beta-blockers (-0.92 mmHg; 95% CI, -1.19, -0.65; P<0.001

13 ly lower in patients previously treated with beta-blockers (3.9 +/- 2.3 mmol/L vs 5.6 +/- 3.6 mmol/L;

14 was higher among patients treated only with beta-blockers (33.3% vs 16.9%, p = 0.017) but not among

15 compared with placebo were as follows: 1991: beta-blockers, 4.01 (CrI, 0.48 to 7.43); 1995: alpha2-ad

16 placebo was greater in patients receiving a beta blocker (-5.76 mm Hg [95% CI -10.28 to -1.23]) or a

17 blockers (66% versus 68%; P=0.04) and early beta-blockers (56% versus 60%; P=0.01).

18 =8399)were treated with a diuretic (80%) and beta-blocker (93%); 47% of those taking a beta-blocker w

19 beta-arrestin bias to the efficacy of select beta-blockers, a specific beta-arrestin-biased pepducin

20 in compensated cirrhosis and the response to beta-blockers according to stage, we performed a prospec

21 mental disorders), in patients treated with beta-blockers, ACE inhibitors or monoamine oxidase inhib

22 beta-blockers act to block excessive catecholamine stimu

23 ation of 5 AMI admission therapies (aspirin, beta-blockers, acute reperfusion therapy, door-to-balloo

24 energic tone and modulated by treatment with beta-blockers; acute afterload stress induces a deeper i

25 Further research into beta-blocker adherence is imperative in this high-risk p

26 We aimed to describe beta-blocker adherence, and predictors thereof, among pa

27 ], angiotensin receptor blockers [ARBs], and beta-blockers adjusted for blood pressure, statins adjus

28 of mortality was lower in patients receiving beta-blockers (adjusted hazard ratio=0.76; 95% confidenc

29 The exposure of interest was beta-blocker administration initiated during the hospita

30 Exposure to beta-blockers after TBI was associated with a reduction

31 inhibitors or angiotensin receptor blockers, beta-blockers, aldosterone antagonists, hydralazine/isos

32 s common to both enantiomers of each studied beta-blocker, allowing thus the simultaneous analysis of

33 compared with placebo plus beta-blocker and beta-blocker alone.

34 luded no active therapy in 47 (8%) patients, beta-blockers alone in 350 (58%) patients, implantable c

35 beta blockers, alone or in combination with digoxin, or

36 istic may influence the effectiveness of the beta-blockers among patients receiving long-term hemodia

37 Use of beta-blockers among patients with new-onset CHD was asso

38 taminants (five antibiotics, an herbicide, a beta-blocker, an antidepressant, and an antineoplastic)

39 nzodiazepines, anxiolytics, antidepressants, beta-blockers, anaesthetic agents and analgesics; length

40 tin prescriptions included male sex, filling beta-blocker and antiplatelet agent prescriptions, and a

41 tandard prophylaxis to prevent rebleeding (a beta-blocker and band ligation) in Spain from October 20

42 y during exercise compared with placebo plus beta-blocker and beta-blocker alone.

43 OMT was defined as prescription of beta-blocker and either angiotensin-converting enzyme in

44 vestigate the association between the use of beta-blockers and 1-year mortality.

45 e was 30 +/- 6 years; and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhi

46 We sought to test the hypothesis that beta-blockers and ACE inhibitors alter the risk for seve

47 beta-Blockers and ACE inhibitors synergistically aggrava

48 beta-Blockers and angiotensin-converting enzyme (ACE) in

49 7%, 18%, and 2%, whereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibito

50 The combination of beta-blockers and band ligation is the standard approach

51 nts with obstruction is medical therapy with beta-blockers and calcium antagonists.

52 Additionally, in 11 patients we withdrew beta-blockers and diuretics and used phenylephrine and a

53 tiseptics, antiepileptics, lipid regulators, beta-blockers and hormones) in eggs and honey was develo

54 y recommended treatment to prevent VRB using beta-blockers and ligation.

55 We obtained information about use of beta-blockers and other medications through linkage with

56 The association between beta-blockers and outcomes differed significantly betwee

57 on in randomized controlled trials comparing beta-blockers and placebo.

58 ersus 25.5% [P=0.01], respectively), whereas beta-blockers and ranolazine were prescribed at similar

59 tors/angiotensin II receptor blockers (ARB), beta-blockers and statins are recommended after acute my

60 nd statins only, 1.17 (95% CI: 1.10 to 1.25) beta-blockers and statins only, 1.19 (95% CI: 1.07 to 1.

61 tion of the cardiovascular drugs metoprolol (beta-blocker) and ramipril (ACE inhibitor) with the anap

62 -dimethyl-4-cyanoaniline (DMABN), sotalol (a beta-blocker) and sulfadiazine (a sulfonamide antibiotic

63 ambient thermal environment), pharmacologic (beta-blockers), and genetic (beta2-AR knockout mice) to

64 only used standard treatments (eg, nitrates, beta blockers, and calcium-channel blockers), emerging a

65 itors, angiotensin receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonist

66 OMT was defined as a combination of statin, beta-blocker, and angiotensin-converting enzyme inhibito

67 ion of at least 1 antiplatelet drug, statin, beta-blocker, and angiotensin-converting enzyme inhibito

68 ors/angiotensin receptor antagonists, use of beta-blocker, and smoking cessation counseling.

69 nzyme inhibitors, 34% (95% CI: 28%-41%) with beta-blockers, and 32% (95% CI: 25%-39%) with mineraloco

70 Receipt of aspirin, beta-blockers, and acute reperfusion therapy on admissio

71 e inhibitors, angiotensin receptor blockers, beta-blockers, and aldosterone antagonists have improved

72 rdiovascular drug classes: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibit

73 cords for statins, calcium channel blockers, beta-blockers, and bisphosphonates.

74 y, and PPV for self-reported use of statins, beta-blockers, and calcium channel blockers were all 95%

75 Statins, beta-blockers, and calcium channel blockers were each re

76 almost perfect agreement for use of statins, beta-blockers, and calcium channel blockers.

77 me inhibitors/angiotensin receptor blockers, beta-blockers, and dual antiplatelet therapy, respective

78 me inhibitors/angiotensin receptor blockers, beta-blockers, and dual antiplatelet therapy.

79 inhibitor/angiotensin II receptor blockers, beta-blockers, and lipid-lowering drugs also increased a

80 e inhibitors, angiotensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonist

81 adeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and statins on survival among older peopl

82 o had prescriptions for ACE inhibitors/ARBs, beta-blockers, and statins, and survived >/=180 days aft

83 ns angiotensin-converting enzyme inhibitors, beta-blockers, and statins.

84 f cardiovascular disease medicines (aspirin, beta blockers, angiotensin-converting enzyme inhibitors,

85 Her medications include a beta-blocker, angiotensin-converting enzyme inhibitor, o

86 y secondary prevention medications (statins, beta-blockers, angiotensin-converting enzyme inhibitors

87 gaps in the use of and patient adherence to beta-blockers, angiotensin-converting enzyme inhibitors/

88 beta blockers are used in symptomatic thyrotoxicosis, an

89 In cardiac surgery, beta-blockers are associated with a lower incidence of s

90 In noncardiac surgery, beta-blockers are associated with a possible increase in

91 Recent data suggest that beta-blockers are associated with prognostic advantages

92 without heart failure (HF), it is unclear if beta-blockers are associated with reduced mortality.

93 Thus, current life-prolonging beta-blockers are contraindicated in patients with both

94 Some beta-blockers are efficiently removed from the circulati

95 ockade than those with CSPH, suggesting that beta-blockers are more suitable to prevent decompensatio

96 Angiotensin-converting enzyme inhibitors and beta-blockers are recommended first-line agents for hear

97 beta-Blockers are used for a wide range of diseases from

98 Nonselective beta-blockers are useful to prevent bleeding in patients

99 ta-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in

100 Are beta-blockers associated with lower rates of mortality a

101 te a potential role for ghrelin in mediating beta blocker-associated hypoglycemia in susceptible indi

102 ta-blocker compared with a low-dialyzability beta-blocker associates with a higher rate of mortality

103 ention (59% vs 22%) and more frequent use of beta blockers at discharge (89% vs 78%).

104 e inhibitor/angiotensin receptor blocker, or beta-blocker) at baseline; these patients had 33% lower

105 (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonis

106 of physicians' preferences for non-selective beta-blockers (BBs) and endoscopic variceal ligation (EV

107 icenter study testing the effect of early IV beta-blockers before PPCI in a general ST-segment elevat

108 The impact of intravenous (IV) beta-blockers before primary percutaneous coronary inter

109 e medication (ACE inhibitors, non-ophthalmic beta blockers, calcium channel blockers, diuretics, and

110 e inhibitors, angiotensin-receptor blockers, beta blockers, calcium-channel blockers, or direct renin

111 ibrillation enrolled in the groups receiving beta-blockers, calcium channel blockers, and digoxin, re

112 Furthermore, beta-blocker carvedilol-mediated beta-arrestin-dependent

113 mine whether new use of a high-dialyzability beta-blocker compared with a low-dialyzability beta-bloc

114 ortality was lower for patients who received beta-blockers compared with those who did not (4.9% vs.

115 d to development of novel methods to control beta-blocker contamination.

116 angiotensin-converting enzyme inhibitors and beta-blockers could prevent trastuzumab-related cardioto

117 amined the effect of study drug according to beta-blocker dose (>/=50% and <50% of target dose) and a

118 or intolerance and the evidence behind using beta-blocker dose and heart rate as therapeutic targets.

119 Discharge beta-blocker dose was indexed to the target beta-blocker

120 This study evaluated the association of beta-blocker dose with survival after acute MI, hypothes

121 o have been stable on a "maximally tolerated beta-blocker dose," but this definition and how to achie

122 ive of previouscoronary revascularization or beta-blocker dose.

123 ents more commonly were not receiving target beta-blocker dose.

124 Lower mortality was observed with all beta-blocker doses (p < 0.0002) versus no beta-blocker t

125 increased survival in patients treated with beta-blocker doses approximating those used in previous

126 Beta-blocker doses used in clinical practice are often s

127 beta-blocker dose was indexed to the target beta-blocker doses used in randomized clinical trials, g

128 -engage in research to establish appropriate beta-blocker dosing after MI to derive optimal benefit f

129 dies, we investigated an association between beta-blocker drug use with improved cancer-specific surv

130 Our results support the concept that beta-blocker drugs may improve the survival of PDAC pati

131 statins, renin-angiotensin system blockers, beta-blockers, dual antiplatelet therapy, and long-term

132 In the randomized controlled Beta-blocker Evaluation of Survival Trial (BEST; 1995-19

133 The beta-Blocker Evaluation of Survival Trial measured LVEF

134 Endoscopic variceal ligation plus beta-blockers (EVL+BB) is currently recommended for vari

135 beta-Blockers exert a prognostic benefit in the treatmen

136 Arrhythmia symptoms and intrauterine beta-blocker exposure each predicted -7 beats per minute

137 beta-Blocker exposure was not randomly allocated in this

138 unctive therapies, such as pretreatment with beta-blockers, ezetimibe, and proprotein convertase subt

139 bleeding, covered TIPS was superior to EVL + beta-blocker for reduction of variceal rebleeding, but d

140 The effectiveness of beta-blockers for preventing cardiac events has been que

141 , 10 (29%) of 35 patients in the endoscopy + beta-blocker group, as compared to 0 of 37 (0%) patients

142 Beta-blockers had no effect on mortality in patients wit

143 Nearly four times more patients treated with beta-blockers had normal blood lactate levels (p< 0.001)

144 vedilol, a currently prescribed nonselective beta-blocker, has been classified as a beta-arrestin-bia

145 Propranolol, a non-selective beta-blocker, has been found to have a tremendous array

146 sease; however, current clinically available beta-blockers have poor selectivity for the cardiac beta

147 be harmful in HF, beta-adrenergic blockers (beta-blockers) have consistently been shown to reduce mo

148 and antihypertensive medications, especially beta-blockers, have been linked to psoriasis development

149 iabetes mellitus and anemia, be treated with beta-blockers, have higher ejection fraction, relative w

150 inhibitor [RAI] and a heart failure-approved beta-blocker [HFBB]) within 90 days before primary preve

151 eveal a significant mortality advantage with beta-blockers; however, quality of evidence is very low.

152 r for patients in sinus rhythm randomized to beta-blockers (HR: 0.73 vs. placebo; 95% CI: 0.67 to 0.7

153 xamine the effects of pharmacotherapies (eg, beta blockers, hydrocortisone, and selective serotonin r

154 To determine if beta-(beta)-blockers improve outcomes after acute traumatic br

155 published reports on the mechanisms by which beta-blockers improve clinical outcomes.

156 idual-patient data to assess the efficacy of beta blockers in patients with heart failure and sinus r

157 angiotensin receptor blockers at admission), beta-blockers in 20.3% (50.5% of eligible), aldosterone

158 We also compared the effects of both beta-blockers in experimental PAH.

159 The Beta-Blockers in Heart Failure Collaborative Group perfo

160 udy was to compare the efficacy of different beta-blockers in long QT syndrome (LQTS) and in genotype

161 Adherence to beta-blockers in LQTS is suboptimal in half of those wit

162 dies are undertaken, however, routine use of beta-blockers in PAH cannot be recommended.

163 rt the strategic use of clinically available beta-blockers in patients to improve responses to immuno

164 s, suggesting limited additional benefit for beta-blockers in patients who were adherent to statins a

165 However, the use of beta-blockers in patients with no cardiac risk factors u

166 We assessed the effects of both beta-blockers in precontracted PA rings.

167 stream repressors of miR-1 as treatment with beta-blockers in pressure-overloaded mouse hearts preven

168 ummarize the current knowledge on the use of beta-blockers in pulmonary hypertension.

169 slight differential increases in the PDC for beta-blockers in the 2012 entry cohort (adjusted differe

170 By analogy with the key role of beta-blockers in the management of left heart failure, s

171 d healthcare delivery system who did not use beta-blockers in the year before entry.

172 Although beta-blockers increase survival in patients with heart f

173 eft cardiac sympathetic denervation included beta-blocker intolerance (15; 32%) or nonadherence (10;

174 0%, type of surgery, and preoperative use of beta-blockers, intra-aortic balloon pump, or catecholami

175 ional stress, for which current therapy with beta-blockers is incompletely effective.

176 The widespread occurrence of the beta-blocker labetalol causes environmental health conce

177 calorically restricted juvenile WT mice with beta blockers led to reduced plasma ghrelin and hypoglyc

178 ance metastasis from primary tumors and that beta-blockers may be protective in breast cancer.

179 edian 2.1 years), 91.5% were discharged on a beta-blocker (mean dose 38.1% of the target dose).

180 beta-Blocker medication reduces the risk of cardiac even

181 Treatment with beta-blocker medication was associated with reduced risk

182 ion fraction of 40.6+/-15.7; all were taking beta-blocker medications.

183 Patients who used beta-blockers (n = 522) had a lower cancer-specific mort

184 side products of the potent antihypertensive beta-blocker nebivolol are reported.

185 were stratified into beta-blocker users and beta-blocker nonusers, and according to the presence of

186 Nonselective beta-blockers (NSBB) are widely used because they have b

187 At these earlier stages, nonselective beta-blockers (NSBBs) have been ineffective in preventin

188 The safety of nonselective beta-blockers (NSBBs) in advanced cirrhosis has been que

189 Treatment of TBI patients with beta-blockers offers a potentially beneficial approach.

190 toprolol, a first-generation beta1-selective beta-blocker, on human cultured PAH and control P-EC pro

191 or being adherent to ACE inhibitors/ARBs and beta-blockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI

192 s/ARBs only, 1.32 (95% CI: 1.21 to 1.44) for beta-blockers only, 1.26 (95% CI: 1.15 to 1.38) statins

193 SHIFT type (P=0.421) were receiving selected beta-blockers, only 58.8% and 67.3% (P<0.001) were on >5

194 y favourable in patients already receiving a beta blocker or calcium-channel blocker.

195 er prevalence of diabetes, hypertension, and beta-blocker or hypnotic treatments.

196 Rate control is usually achieved with a beta-blocker or non-dihydropyridine calcium channel bloc

197 gher blood pressure and those treated with a beta-blocker or randomized to valsartan had greater odds

198 of severe anaphylaxis after monotherapy with beta-blockers or ACE inhibitors, which was more pronounc

199 tients receiving rate-control treatment with beta-blockers or calcium channel blockers, and the use o

200 st follow-up, 39 (64%) patients were only on beta-blockers or no treatment, 21 were on class 1 or 3 a

201 t follow-up, 128 (45%) patients were only on beta-blockers or no treatment, 41 (15%) were on sotalol

202 rho = -0.43, P = 0.003), and treatment with beta-blockers (P = 0.001).

203 ed at 90 days and 1 year after discharge for beta-blockers, platelet P2Y12 receptor inhibitors, stati

204 When beta-blockers produce reverse-remodeling in idiopathic d

205 a single dose of 40 mg of the noradrenergic beta-blocker propranolol (n = 15), double-blind and plac

206 bled the detection and quantification of the beta-blocker propranolol spiked into human serum, plasma

207 fer voltammetric detection of the protonated beta-blocker propranolol was explored at arrays of nanos

208 mode of action through co-treatment with the beta-blocker propranolol, while leaving the peripheral e

209 re and after 1 wk of oral treatment with the beta-blocker propranolol.

210 vention of adrenergic-induced arrhythmias by beta-blockers (propranolol and carvedilol), flecainide,

211 No clear rate differences were observed by beta-blocker receptor selectivity.

212 beta-Blockers reduce mortality and improve symptoms in p

213 Regardless of pre-treatment heart rate, beta-blockers reduce mortality in patients with heart fa

214 Beta-blockers reduced ventricular rate by 12 beats/min i

215 get for beta-adrenergic antagonists, such as beta-blockers, relatively little is yet known about its

216 Patients received beta-blockers, renin-angiotensin system antagonists, and

217 idation peaks toward the R-antipodes of four beta-blocker representatives and additional oxidation pe

218 multaneous enantiospecificity toward several beta-blocker representatives extensively used in the pha

219 nhibitors/angiotensin receptor blockers, and beta-blockers, respectively.

220 , 88,542 (96.4%) and 81,933 (93.2%) received beta-blockers, respectively.

221 In both groups, HVPG and acute beta-blocker response were evaluated at baseline and HVP

222 Based on our findings, beta blockers should not be used preferentially over oth

223 operatively, whereas the decision to start a beta-blocker should be individualized, weighing risks an

224 pleens from human tissue donors treated with beta-blocker showed enhanced vascular cell adhesion mole

225 trial of patients with CPVT, flecainide plus beta-blocker significantly reduced ventricular ectopy du

226 before and after treatment with amiodarone, beta-blockers, sotalol, or ablation.

227 nists, diuretics, stimulants, narcotics, and beta-blockers) spiked in human urine and plasma samples.

228 nicians actively initiating and up-titrating beta-blockers that may aid in achieving maximally tolera

229 rden on Holter or treadmill testing received beta-blocker therapy (17%).

230 is and septic shock: survival (p = 0.03) and beta-blocker therapy (p = 0.01).

231 Beta-blocker therapy after acute myocardial infarction (

232 added to beta-blocker therapy is superior to beta-blocker therapy alone for the prevention of exercis

233 hic ventricular tachycardia received routine beta-blocker therapy and demonstrated >90% long-term com

234 ncreased the risk of recurrent SCAD, whereas beta-blocker therapy appeared to be protective.

235 ity of SCAD patients were taking aspirin and beta-blocker therapy at discharge and at follow-up.

236 ole in lactate production and that long-term beta-blocker therapy could affect the lactate concentrat

237 Long-term beta-blocker therapy decreases blood lactate concentrati

238 ey potentially offer a truly cardioselective beta-blocker therapy for the large number of patients wi

239 rt study, evidence of a lower mortality with beta-blocker therapy in AF patients with concomitant HF

240 enefit for antiplatelet, lipid-lowering, and beta-blocker therapy in both the CABG and PCI groups (P=

241 rapolated; the efficacy of ACE inhibitor and beta-blocker therapy in childhood cancer survivors with

242 ide dosed to therapeutic levels and added to beta-blocker therapy is superior to beta-blocker therapy

243 e initial assessment of septic patients with beta-blocker therapy may underestimate the severity of t

244 assessed the effect of circadian rhythm and beta-blocker therapy over traditional time and frequency

245 ise test while receiving maximally tolerated beta-blocker therapy that was continued throughout the t

246 Beta-blocker therapy was also prescribed.

247 ter acute MI, hypothesizing that higher dose beta-blocker therapy will be associated with increased s

248 beta-blocker therapy, VT of ischemic origin, and complet

249 ll beta-blocker doses (p < 0.0002) versus no beta-blocker therapy.

250 bitors and angiotensin II receptor blockers, beta-blockers, thiazide diuretics, calcium channel block

251 .4; 95% CI 1.1-5.3; P = 0.0376), and ongoing beta-blocker treatment (OR = 4.2; 95% CI 1.8-9.8; P = 0.

252 s encompassing 2005 unique TBI patients with beta-blocker treatment and 6240 unique controls.

253 We aimed to investigate associations between beta-blocker treatment and cardiovascular outcome and mo

254 of cardiovascular disease receiving ongoing beta-blocker treatment and undergoing surgery in an emer

255 ermine the hazard ratio (HR) associated with beta-blocker treatment and used treatment-by-covariate i

256 t angiotensin-converting enzyme inhibitor or beta-blocker treatment for patients with positive test r

257 iation was accompanied with indications that beta-blocker treatment is also associated with a better

258 h-throughput data for studying the effect of beta-blocker treatment on heart failure patients.

259 If tolerated, long-term beta-blocker treatment should be continued perioperative

260 variceal ligation (EVL) or glue injection + beta-blocker treatment was compared with TIPS placement

261 MINOCA, a trend toward a positive effect of beta-blocker treatment, and a neutral effect of dual ant

262 nts and the respective propensity scores for beta-blocker treatment.

263 was used to compare event rates according to beta-blocker usage status.

264 per week, 561 [52.8%]; P < .001), and lower beta-blocker use (73 [6.9%]; P < .001) compared with low

265 in mortality between those with and without beta-blocker use (average treatment effect [ATE] coeffic

266 (beta-Blocker Use and Mortality in Hospital Survivors of

267 udy was to determine the association between beta-blocker use and mortality in patients with AMI with

268 ncreased (hazard ratio: 2.46; p = 0.011) and beta-blocker use diminished (hazard ratio: 0.36; p = 0.0

269 or cancer-specific mortality associated with beta-blocker use during the 90-day period before cancer

270 unctional outcome, and quality of life after beta-blocker use for TBI.

271 Although systemic beta-blocker use was associated with lower IOP and syste

272 beta-Blocker use was determined if a dose was ordered at

273 Systemic beta-blocker use was independently associated with an IO

274 However, beta-blocker use was not associated with lower cardiovas

275 Propensity scores for beta-blocker use were derived from 52 baseline clinical

276 ed 2:1 based on age and propensity score for beta-blocker use, yielding 5496 treated and 2748 untreat

277 the time of transplant, type 2 diabetes, and beta-blocker use.

278 aspirin was explained by concurrent systemic beta-blocker use.

279 tched pairs of PAH patients with and without beta-blocker use.

280 Patients were stratified into beta-blocker users and beta-blocker nonusers, and accord

281 angiotensin-converting enzyme inhibitors and beta blockers was performed over 6 months.

282 itiation of a high- versus low-dialyzability beta-blocker was associated with a higher risk of death

283 In contrast, use of beta-blocker was not associated with an improved 30-day

284 examine the influence of healthy user bias, beta-blocker was used as an active comparator.

285 or calcium channel blockers, and the use of beta-blockers was associated with the largest risk reduc

286 The use of beta-blockers was less common but use of beta2-adrenergi

287 LVSD as recorded in the hospital, the use of beta-blockers was not associated with a lower risk of de

288 eptor blockers, calcium channel blockers, or beta blockers) was significantly better than thiazides a

289 on of follow-up days patients were dispensed beta-blocker) was calculated.

290 beta blockers were inferior to other drugs for the preve

291 nd beta-blocker (93%); 47% of those taking a beta-blocker were treated with >/=50% of the recommended

292 beta-Blockers were almost universally initiated; however

293 In the matched HFREF cohort, beta-blockers were associated with reduced mortality (HR

294 beta-Blockers were prescribed in 205 of 211 patients (97

295 Long-term beta-blockers were prescribed to 74 patients (82%).

296 described as intolerable by 6 (8%) and their beta-blockers were stopped.

297 Antiarrhythmic drugs, including beta-blockers, were discontinued 4 weeks after PVI.

298 s mimics the hypertrophy seen with broad TGF-beta blockers, while avoiding the adverse effects due to

299 re used to compare the efficacy of different beta-blockers with the risk of cardiac events in LQTS.

300 yopathy (age, 49+/-17 years; 60% men; 57% on beta-blockers) with a basal septal thickness of </=1.8 c